History | Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | Guidance | NICE

History

A list of downloadable documents created during development.

Expected publication

Equality Impact Assessment (Guidance development) ^{PDF 172 KB} 21 February 2023
Register of interests ^{PDF 322 KB} 29 March 2023

Final draft guidance

Final draft guidance
Final appraisal document ^{PDF 518 KB} 21 February 2023
Committee papers ^{PDF 10.21 MB} 21 February 2023
Public committee slides ^{PDF 1.95 MB} 21 February 2023
Public committee slides - in vitro presentation ^{PDF 8.57 MB} 21 February 2023

Draft guidance

Draft guidance
Appraisal consultation document (PDF version) ^{PDF 391 KB} 16 November 2022
Appraisal consultation document (online commenting)
Committee papers ^{PDF 15.32 MB} 16 November 2022
Public committee slides ^{PDF 2.48 MB} 16 November 2022

Invitation to participate

Final scope ^{PDF 249 KB} 01 August 2022
Final stakeholder list ^{PDF 174 KB} 01 August 2022
NICE's response to comments on the draft scope and provisional stakeholder list ^{PDF 1.35 MB} 01 August 2022
Equality impact assessment (Scoping) ^{PDF 137 KB} 01 August 2022
Statement from NICE and the SMC/HIS ^{PDF 93 KB} 28 September 2022

Assessment report sent for information

Assessment report ^{PDF 1.17 MB} 11 July 2022

Invitation to participate

Final scope ^{PDF 246 KB} 19 April 2022
Provisional Stakeholder List (post-referral) ^{PDF 172 KB} 19 April 2022
Final protocol ^{PDF 384 KB} 19 April 2022
Supporting documentation - Stakeholder Information Meeting slides ^{PDF 212 KB} 19 April 2022
Supporting documentation - Process statement ^{PDF 163 KB} 28 September 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope pre referral ^{PDF 251 KB} 14 January 2022
Draft matrix post referral ^{PDF 187 KB} 02 February 2022